Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.

MLA

De Luca, Andrea, et al. “Lopinavir/Ritonavir or Efavirenz plus Two Nucleoside Analogues as First-Line Antiretroviral Therapy: A Non-Randomized Comparison.” Antiviral Therapy, vol. 11, no. 5, 2006, pp. 609–18. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=16964829&authtype=sso&custid=ns315887.

APA

De Luca, A., Cozzi-Lepri, A., Antinori, A., Zaccarelli, M., Bongiovanni, M., Di Giambenedetto, S., Marconi, P., Cicconi, P., Resta, F., Grisorio, B., Ciardi, M., Cauda, R., & Monforte, A. d’Arminio. (2006). Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison. Antiviral Therapy, 11(5), 609–618.

Chicago

De Luca, Andrea, Alessandro Cozzi-Lepri, Andrea Antinori, Mauro Zaccarelli, Marco Bongiovanni, Simona Di Giambenedetto, Patrizia Marconi, et al. 2006. “Lopinavir/Ritonavir or Efavirenz plus Two Nucleoside Analogues as First-Line Antiretroviral Therapy: A Non-Randomized Comparison.” Antiviral Therapy 11 (5): 609–18. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=16964829&authtype=sso&custid=ns315887.